Search research articles
Contact Us
Filters
Showing results (91-100 of 119) with videos related to
Page
of 12
Sort By:
Lancet (London, England)
|
May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B McInnes, Frank Behrens, Philip J Mease, et al.
RMD Open
|
August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
Laura C Coates, Ricardo Blanco, Frank Behrens, et al.
Therapeutic Advances in Musculoskeletal Disease
|
April 3, 2026
Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative
Oliver FitzGerald, Catherine Smith, Christine Huppertz, et al.
Journal of Thrombosis and Haemostasis : JTH
|
January 25, 2023
An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study
Christof Geisen, Mette Kjaer, Erika Fleck, et al.
Journal of Clinical Medicine
|
December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Annals of the Rheumatic Diseases
|
January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
Ronald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Annals of the Rheumatic Diseases
|
May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group
Jérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Arthritis Research & Therapy
|
June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
Christopher P Denton, Jerome Avouac, Frank Behrens, et al.
Rheumatology (Oxford, England)
|
March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
The Journal of Rheumatology
|
October 4, 2011
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
Otylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 119) with videos related to
Sort By:
Page
of 12
Lancet (London, England)
|
May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial
Iain B McInnes, Frank Behrens, Philip J Mease, et al.
RMD Open
|
August 25, 2025
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
Laura C Coates, Ricardo Blanco, Frank Behrens, et al.
Therapeutic Advances in Musculoskeletal Disease
|
April 3, 2026
Definition of the terms used to describe psoriatic disease datasets: a HIPPOCRATES initiative
Oliver FitzGerald, Catherine Smith, Christine Huppertz, et al.
Journal of Thrombosis and Haemostasis : JTH
|
January 25, 2023
An HPA-1a-positive platelet-depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo-controlled, single-center, phase 1/2 proof-of-concept study
Christof Geisen, Mette Kjaer, Erika Fleck, et al.
Journal of Clinical Medicine
|
December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
Annals of the Rheumatic Diseases
|
January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial
Ronald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Annals of the Rheumatic Diseases
|
May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group
Jérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Arthritis Research & Therapy
|
June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
Christopher P Denton, Jerome Avouac, Frank Behrens, et al.
Rheumatology (Oxford, England)
|
March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)
Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
The Journal of Rheumatology
|
October 4, 2011
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)
Otylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Page
of 12